Back to top

Image: Bigstock

GW Pharmaceuticals, NetGear, Cisco Systems and NetApp highlighted as Zacks Bull and Bear of the Day

Read MoreHide Full Article

For Immediate Release

Chicago, IL – November 14, 2019 – Zacks Equity Research Shares of GW Pharmaceuticals GWPH as the Bull of the Day, NetGear NTGR asthe Bear of the Day. In addition, Zacks Equity Research provides analysis on Cisco Systems CSCO and NetApp (NTAP - Free Report) .

Here is a synopsis of all four stocks:

Bull of the Day:

GW Pharmaceuticalsis the $3.5 billion biotechnology company with the first FDA-approved cannabis-derived drug. Epidiolex was created and tested starting four years ago for the treatment of two rare forms of childhood epilepsy and launched commercially one year ago.

For more on the 20-year history of GW Pharma research and development in cannabis-based medicines, see my September Bull of the Day.

On November 5, GW released third-quarter results and announced Epidiolex U.S. year-to-date net sales of $188.0 million, including Q3 net sales of $86.1 million. Here were other highlights from the quarter...

**Over 15,000 patients have received Epidiolex prescriptions since launch

**Over 3,000 physicians have generated dispensed prescriptions since launch

**Strong payor coverage with approximately 93 percent of all Commercial, Medicaid and Medicare lives in the US having a coverage determination, of which 65 percent are PA to indication or less restrictive

The insurance reimbursement factor is extremely important as doctors may choose Epidiolex for their patients but payers may still making adjustments to allow cannabinoid medicines into their approved protocols yet. 

But the November 5 GW Pharma report didn't "wow the crowd" because the sales growth this quarter wasn't as dramatic as the prior two since the Epidiolex launch. And thus the gap down in GWPH shares of over 15% the following day.

And I saw that drop to $110 as a buying opportunity. Here was the buy alert to my TAZR Trader members last week... 

GW Pharmaceuticals: Buying between $105 and $115 over the next week.

Despite the top and bottom beats, there was concern in the GWPH quarter about discontinued prescriptions and a slower growth rate of new patients.

But overall, much of the risk has been taken out of the stock -- with projected 2020 sales growth of 93% to $580 million -- and I look for it to bottom near/above the Oct lows of $105.

Here were some of the analyst reactions to the quarter...

Piper Jaffray:Analyst Danielle Brill lowered her price target for GW Pharmaceuticals to $160 from $210 saying the ceiling for Epidiolex may be lower than originally projected due to patient discontinuations. However, she does "not think we're close to hitting a plateau" following GW's Q3 results. In the midterm, the analyst expects the ongoing European launch, additional off-label usage and label expansion into the tuberous sclerosis complex to serve as primary drivers of growth. Brill, who lowered her peak sales estimate for Epidiolex to $1.5B from $2.0B, believes the 12% post-earnings selloff in shares of GW Pharmaceuticals is overdone. Continued growth over the coming quarters should "restore confidence and drive shares higher," she says. The analyst keeps an Overweight rating on the stock.

Stifel Nicolaus:Reiterate their Buy rating on a 3Q19 that may inevitably raise questions surrounding the Epidiolex runway, but ultimately provides a buying opportunity for the stock on weakness. The analysts decreased their numbers for 4Q and 2020, as they acknowledge being overly optimistic heading into 3Q. But they still think current consensus -- specifically, Street estimates published before last night's report -- remain beatable. This view takes GW management commentary at face value, that the Epidiolex patient add rate (~3000) observed from 2Q-to-3Q, while slower than 2Q, is sustainable going forward. Stifel analysts also think the potential for improving access in 2020 could represent an upside lever that isn't accounted for in Street estimates. PT lowered from $228 to $215.

Morgan Stanley:Analyst David Lebowitz said GW Pharmaceuticals' U.S. Epidiolex sales of about $86M in Q3 "ultimately is a strong number that supports long-term projections," but it also is likely short of investors' high expectation following "dramatic beats" posted in the first two full quarters of the drug being on the market. Epidiolex has been prescribed by over 3,000 physicians, which is up from 2,500, and the target prescribing base remains 6,000, noted Lebowitz. He would be a buyer on any weakness given his unchanged view on the drug's long-term prospects and keeps an Overweight rating on GW shares with a slightly lowered price target of $231, down from $233.

Oppenheimer:Analyst Esther Rajavelu lowered her price target for GW Pharmaceuticals to $222 following the company's quarterly results, saying Q3 revenues were in line with estimates. Though GW Pharmaceuticals met her Q3 topline expectations, Rajavelu tells investors in a research note that she is lowering Epidiolex revenue estimates for future periods as she anticipates moderating new patient numbers and higher attrition rates. She keeps an Outperform rating on the shares, as she continues to believe Epidiolex use in multiple seizure types is not fully reflected in the stock at current levels.

Bottom line: the only FDA-approved pipeline for cannabis-derived medicines could have dozens of products at some point, especially with label expansion opportunities.

And the new FDA approvals could launch the stock back toward $200 very quickly.

This is a revolutionary pharma company growing sales to over $500 million next year and probably $1 billion by 2022. At a sub-$4 billion market cap, that's a buy.

(end of TAZR buy alert commentary on Nov 6)

European Update

If you read my September article, you know that GW Pharma was founded in the UK in 1998 and has been solely focused on medical cannabis R&D for over two decades.

And their first UK government approval was for Sativex in the treatment of multiple sclerosis (MS) in 2010. 

Here were the bullets that GW Pharma shared in their Nov 5 press release on Epidiolex...

**European Commission approval in September 2019

**Commercialization underway in France and Germany

**UK NICE guidance expected in Q4 2019; Spain and Italy launches to follow in 2020

**Early Access Program now includes over 1,100 patients across 5 major EU countries, and over 400 physicians from 250 top epilepsy centers

Then on Nov 10, the company revealed that they received a positive NICE recommendation for EPIDYOLEX® (cannabidiol) oral solution for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy. 

GW said in a press release that two of its medicines, EPIDYOLEX (cannabidiol) oral solution and Sativex (nabiximols), have been recommended by the UK’s National Institute for Health and Care Excellence (NICE) to receive routine reimbursement from NHS England.

As mentioned earlier, medical financial coverage and reimbursement by national health organizations and insurance carriers is key to the growth of drugs in a new category like those derived from cannabis.

Analysts at SVB Leerink found this news very positive and noted "We remain confident that Epidiolex can be >$1B product and believe that eventually investors will look through quarterly prints and see this opportunity."

The healthcare-focused investment bank reiterated their Outperform rating and $198 price target.

Disclosure: I own GWPH shares for the Zacks TAZR Trader portfolio.

Bear of the Day:

NetGearis an $800 million provider of networking and Internet connected products for broadband access and network connectivity.

The stock has been in and out of the cellar of the Zacks Rank since August and just got kicked down there again after their earnings report on October 23 where both revenues and profits declined year over year.

The outlook wasn't too bright either, which caused analysts to lower their estimates once again. Since the report three weeks ago, full-year 2019 EPS projections dropped 19% from $2.27 to $1.83 and 2020 profit views fell 22% from $2.73 to $2.12.

My colleague Dave Borun last wrote about NetGear as the Bear of the Day in mid-August when shares were trading above $33. Here's what he had to say...

It’s not a great time to be in the network equipment business. The US-China trade dispute threatens to increase prices for firms which are heavily dependent on Chinese manufacturing and a threatened global economic slowdown would mean significantly reduced demand for finished products.

Netgear now finds itself stuck between the proverbial rock and hard place, with planned tariffs potentially increasing the cost of its products – manufacturing of which is outsourced to several other companies, primarily in China and Vietnam – just as demand for its commercial networking equipment seems likely to wane.

The products Netgear makes for the home consumer market tend to sell consistently, regardless of economic conditions, but the businesses that purchase more expensive switches, network appliances and storage solutions tend to ramp up their spending during boom times and cut back sharply when times are tougher.

(end of excerpt from Dave Borun's August 15 article)

What Dave was seeing and hearing then is still true today as tariff and global growth headwinds continue to impact NetGear.

Since the company has sales bigger than its market cap, it may remain a value play or potential M&A target.

But until the estimates stop going down, and start heading back up, it's best to stand aside. The Zacks Rank will let you know.

Additional content:

Cisco Beats but Falls on Guidance, NetApp Mixed

Cisco Systems has once again outperformed estimates in its fiscal Q1 2020 earnings report, which was released after the closing bell Wednesday. Earnings of 84 cents per share was up 12% year over year and 3 cents higher than the Zacks consensus. Revenues of $13.2 billion in the quarter surpassed the $13.02 billion expected, partially on stronger software subscriptions.

However, lower-than-expected earnings for its fiscal Q2 are sending shares down 4.5% in late trading. While we had expected earnings on 80 cents to be reported in the ongoing quarter, the company now expects 75-77 cents per share, down 3-5% year over year. Concerns over its Enterprise business seems to play a role here. Cisco has outperformed estimates in each quarter going back to the Zacks reconfiguration of stock-based compensation, in fiscal Q2 2017. For more on CSCO's earnings, click here.

Silicon Valley-based NetApp, a cloud data services provider, posted mixed results in its fiscal Q2 2020 quarter after Wednesday's close. $1.09 per share easily outpaced the 94 cents expected. and even topped the year-ago quarter by 3 cents per share, though revenues of $1.37 billion missed the $1.39 billion Zacks consensus estimate, which itself was a drop of 8.6% year over year. Cloud Data Services rose 167% year over year to $72 million in the quarter. The company is also introducing a new Senior VP and Chief Marketing Officer, James Whitemore. George Kurian remains company CEO. For more on NTAP's earnings, click here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339 provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

NetApp, Inc. (NTAP) - free report >>